Abstract
In our previous study, X-31ca-based H5N1 LAIVs, in particular, became more virulent in mice than the X-31ca MDV, possibly by the introduction of the surface antigens of highly pathogenic H5N1 influenza virus, implying that additional attenuation is needed in this cases to increase the safety level of the vaccine. In this report we suggest an approach to further increase the safety of LAIV through additional cold-adapted mutations in the hemagglutinin. The cold-adaptation of X-31 virus resulted in four amino acid mutations in the HA. We generated a panel of 7:1 reassortant viruses each carrying the hemagglutinins with individual single amino acid mutations. We examined their phenotypes and found a major attenuating mutation, N81K. This attenuation marker conferred additional temperature-sensitive and attenuation phenotype to the LAIV. Our data indicate that the cold-adapted mutation in the HA confers additional attenuation to the LAIV strain, without compromising its productivity and immune response.
| Original language | English |
|---|---|
| Pages (from-to) | 1-9 |
| Number of pages | 9 |
| Journal | Virology |
| Volume | 491 |
| DOIs | |
| Publication status | Published - 2016 Apr 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Virology
Cite this
}
Enhancement of the safety of live influenza vaccine by attenuating mutations from cold-adapted hemagglutinin. / Lee, Yoon Jae; Jang, Yo Han; Kim, Paul; Lee, Yun Ha; Lee, Young Jae; Byun, Young Ho; Lee, Kwang Hee; Kim, Kyusik; Seong, Baik Lin.
In: Virology, Vol. 491, 01.04.2016, p. 1-9.Research output: Contribution to journal › Article
TY - JOUR
T1 - Enhancement of the safety of live influenza vaccine by attenuating mutations from cold-adapted hemagglutinin
AU - Lee, Yoon Jae
AU - Jang, Yo Han
AU - Kim, Paul
AU - Lee, Yun Ha
AU - Lee, Young Jae
AU - Byun, Young Ho
AU - Lee, Kwang Hee
AU - Kim, Kyusik
AU - Seong, Baik Lin
PY - 2016/4/1
Y1 - 2016/4/1
N2 - In our previous study, X-31ca-based H5N1 LAIVs, in particular, became more virulent in mice than the X-31ca MDV, possibly by the introduction of the surface antigens of highly pathogenic H5N1 influenza virus, implying that additional attenuation is needed in this cases to increase the safety level of the vaccine. In this report we suggest an approach to further increase the safety of LAIV through additional cold-adapted mutations in the hemagglutinin. The cold-adaptation of X-31 virus resulted in four amino acid mutations in the HA. We generated a panel of 7:1 reassortant viruses each carrying the hemagglutinins with individual single amino acid mutations. We examined their phenotypes and found a major attenuating mutation, N81K. This attenuation marker conferred additional temperature-sensitive and attenuation phenotype to the LAIV. Our data indicate that the cold-adapted mutation in the HA confers additional attenuation to the LAIV strain, without compromising its productivity and immune response.
AB - In our previous study, X-31ca-based H5N1 LAIVs, in particular, became more virulent in mice than the X-31ca MDV, possibly by the introduction of the surface antigens of highly pathogenic H5N1 influenza virus, implying that additional attenuation is needed in this cases to increase the safety level of the vaccine. In this report we suggest an approach to further increase the safety of LAIV through additional cold-adapted mutations in the hemagglutinin. The cold-adaptation of X-31 virus resulted in four amino acid mutations in the HA. We generated a panel of 7:1 reassortant viruses each carrying the hemagglutinins with individual single amino acid mutations. We examined their phenotypes and found a major attenuating mutation, N81K. This attenuation marker conferred additional temperature-sensitive and attenuation phenotype to the LAIV. Our data indicate that the cold-adapted mutation in the HA confers additional attenuation to the LAIV strain, without compromising its productivity and immune response.
UR - http://www.scopus.com/inward/record.url?scp=84957575811&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84957575811&partnerID=8YFLogxK
U2 - 10.1016/j.virol.2016.01.022
DO - 10.1016/j.virol.2016.01.022
M3 - Article
VL - 491
SP - 1
EP - 9
JO - Virology
JF - Virology
SN - 0042-6822
ER -